Ketorolac Tromethamine Tablet, Film Coated
FDA Label NDC 60687-104

68 label sections · Submitted to the FDA by American Health Packaging · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by American Health Packaging for the product Ketorolac Tromethamine (NDC 60687-104). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning, description, pharmacodynamics, pharmacokinetics, comparison of iv, im and oral pharmacokinetics, linear kinetics, absorption, distribution, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

Fetal Toxicity

Premature Closure of Fetal Ductus Arteriosus:
Avoid use of NSAIDs, including ketorolac tromethamine tablets, in pregnant women at about 30 weeks gestation and later. NSAIDs including ketorolac tromethamine tablets, increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age.

Oligohydramnios/Neonatal Renal Impairment:
Use of NSAIDs, including ketorolac tromethamine tablets, at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation. In some postmarketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required. If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit ketorolac tromethamine tablets use to the lowest effective dose and shortest duration possible. Consider ultrasound monitoring of amniotic fluid if ketorolac tromethamine tablets treatment extends beyond 48 hours. Discontinue ketorolac tromethamine tablets if oligohydramnios occurs and follow up according to clinical practice (see PRECAUTIONS; Pregnancy).

Packaging Information

American Health Packaging unit dose blisters (see How Supplied section) contain drug product from Teva Pharmaceuticals as follows:
(10 mg / 30 UD) NDC 60687-104-21 packaged from NDC 0093-0314

Distributed by:
American Health Packaging
Columbus, OH 43217

8410421/0725

Package/Label Display Panel – Carton – 10 Mg

NDC 60687- 104-21

Ketorolac Tromethamine
Tablets, USP

10 mg

30 Tablets (3 x 10)                 Rx Only

PHARMACIST: Dispense with Medication Guide to each patient.

Each Film-Coated Tablet Contains:
Ketorolac Tromethamine, USP................................................10 mg

Usual Dosage: One tablet every 4 to 6 hours. See full prescribing
information.

Store at 20° to 25°C (68° to 77°F); excursions permitted between
15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
PROTECT FROM LIGHT AND EXCESSIVE HUMIDITY.

FOR YOUR PROTECTION: Do not use if blister is torn or broken.

The drug product contained in this package is from
NDC # 0093-0314, Teva Pharmaceuticals.

Distributed by: American Health Packaging, Columbus, Ohio 43217

710421
0410421/0824

Package/Label Display Panel – Blister – 10 Mg

10mg Ketorolac Tromethamine Blister (Image 02)

10mg Ketorolac Tromethamine Blister (Image 02)

Ketorolac Tromethamine
Tablet USP

10 mg

* Please review the disclaimer below.